Potent and selective allosteric inhibitor of Akt (IC50s: Akt1 = 5 nM, Akt2 = 12 nM, Akt3 = 65 nM) that enhances the in vitro and in vivo antitumor efficacy of several standard chemotherapeutic agents. It was able to decrease insulin-stimulated glucose uptake, glycogen synthesis and glycogen synthase activity in rat muscle. MK-2206 induced G1-phase cycle arrest and sensitized HepG2 hepatocellular carcinoma cells to TRAIL-induced apoptosis.; Purity: > 98%; Molecular Weight: 480.39; Form/Appearance: powder, 25 mg